Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$595.73 USD

595.73
733,122

+5.74 (0.97%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

SmileDirectClub (SDC) Q4 Earnings Lag Estimates, Margin Falls

by Zacks Equity Research

SmileDirectClub (SDC) reports lower-than-expected results for the fourth quarter, issues full-year 2022 sales guidance.

Here's Why You Should Invest In Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth in its consumer-centric digital solutions.

National Vision (EYE) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.

McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up

by Zacks Equity Research

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.

Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down

by Zacks Equity Research

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish

by Zacks Equity Research

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.

Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.

What Makes McKesson (MCK) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.

Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.

Should Value Investors Buy These Medical Stocks?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

3 Reasons Why McKesson (MCK) Is a Great Growth Stock

by Zacks Equity Research

McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.